Brain metastases from hepatocellular carcinoma: recent advances and future avenues

Shanshan Wang; Anqiang Wang; Jianzhen Lin; Yuan Xie; Liangcai Wu; Hanchun Huang; Jin Bian; Xiaobo Yang; Xueshuai Wan; Haitao Zhao; Jiefu Huang

doi:10.18632/oncotarget.15730

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Brain metastases from hepatocellular carcinoma: recent advances and future avenues

Shanshan Wang, Anqiang Wang, Jianzhen Lin, Yuan Xie, Liangcai Wu, Hanchun Huang, Jin Bian, Xiaobo Yang, Xueshuai Wan, Haitao Zhao _ and Jiefu Huang

PDF | HTML | How to cite

Oncotarget. 2017; 8:25814-25829. https://doi.org/10.18632/oncotarget.15730

Metrics: PDF 2746 views | HTML 5776 views | ?

Abstract

Shanshan Wang1,*, Anqiang Wang1,*, Jianzhen Lin1,*, Yuan Xie1, Liangcai Wu1, Hanchun Huang1, Jin Bian1, Xiaobo Yang1, Xueshuai Wan1, Haitao Zhao1,2 and Jiefu Huang1

1 Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

2 Center of Translational Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

* These authors have contributed equally to this work

Correspondence to:

Haitao Zhao, email:

Jiefu Huang, email:

Keywords: brain metastases, hepatocellular carcinoma, radiotherapy, targeted therapy, immunotherapy

Received: November 21, 2016 Accepted: February 07, 2017 Published: February 25, 2017

Abstract

The incidence of brain metastases from hepatocellular carcinoma (BMHCC) is becoming more frequent than that of the past as a result of prolonged survival of patients with HCC. Compared with brain metastases from other types of cancer, BMHCC tends to exhibit a high incidence of intracerebral hemorrhage (ICH) and poor liver function. Unfortunately, the prognosis is extremely poor for patients with BMHCC owing to the limited treatment selection. Currently, optimal treatment requires multidisciplinary approaches including surgery, whole-brain radiation therapy and stereotactic radiosurgery. Besides these traditional approaches, novel treatments such as target therapy and immunotherapy provide an opportunity to improve the survival of these patients. This review provides an overview of the incidence, characteristics, prognosis, and current and potential future management strategies for BMHCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15730

Publication Alerts

Reviews:

Brain metastases from hepatocellular carcinoma: recent advances and future avenues

Abstract